Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421994 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD | |
| SCHEMBL6551228 | 0.83 | TSHR (0.56) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD | |
| SCHEMBL5133401 | 0.83 | RAB9A (0.38) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD | |
| SCHEMBL3785486 | 0.83 | TSHR (0.53) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD | |
| SCHEMBL17707769 | 0.83 | CRHBP (0.46) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD | |
| SCHEMBL16957915 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD | |
| SCHEMBL7369896 | 0.82 | TSHR (0.54) | ALDH1A1KMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL1032670 | 0.82 | ALDH1A1 (0.68) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD | |
| SCHEMBL30662861 | 0.82 | TSHR (0.58) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD | |
| SCHEMBL206164 | 0.82 | TSHR (0.58) | ALDH1A1KMT2ASMN1; SMN2MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4620470-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4615455-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-9073926-B2 | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| EP-2509979-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| CN-102574814-A | Process for preparation of pyrimidinylacetonitrile derivatives and intermediates for synthesis thereof | IHARA CHEMICAL IND CO | 2012-07-11 | — | — | CN | disclosed |
| WO-2011071725-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| US-20110071136-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071136-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011035019-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| CN-1863789-A | Substituted isoquinolinones | PORTOLA PHARM INC (US) | 2006-11-15 | — | — | CN | disclosed |
| US-5543550-A | NITRATING ALKYL ESTER OF 3-FLUOROBENZOIC ACID DISSOLVED IN SOLVENT-FREE SULFURIC ACID, THEN ADDING WATER, SEPARATION, HYDROLYSIS, PRESSURIZED CATALYTIC HYDROGENATION OF THE NITRATED ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | ALDH1A1 4348/4885KMT2A 289/4885SMN1; SMN2 1781/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885KMT2A 445/4885SMN1; SMN2 2647/4885 |
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885KMT2A 3149/4885SMN1; SMN2 4551/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | ALDH1A1 3721/4885KMT2A 605/4885SMN1; SMN2 960/4885 |
| US-20110071136-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | PACSIN2, CSNK2A3, CKS2 | ALDH1A1 4683/4885KMT2A 1493/4885SMN1; SMN2 4694/4885 |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | PKD1, PAH, JAK2 | ALDH1A1 249/4885KMT2A 2584/4885SMN1; SMN2 1330/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | ALDH1A1 274/4885KMT2A 1639/4885SMN1; SMN2 1434/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | ALDH1A1 2904/4885KMT2A 99/4885SMN1; SMN2 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.